SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 16, 2002

ENZON, INC.
(Exact name of registrant as specified in its charter)

Delaware                       0-12957                        22-237286
(State or other jurisdiction        (Commission                   (IRS Employer
of incorporation)              File Number)                 Identification)

20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 980-4500

N/A
(Former name or former address, if changed since last report)

Item 5.  Other Events

Enzon, Inc. announced today that Schering-Plough Corporation has advised it
of the following:

o    Prior to the launch of the combination  therapy of PEG-INTRON(TM)
and   REBETOL(R)   in  the  United   States  in   October   2001,
Schering-Plough  initiated a program called the PEG-INTRON Access
Assurance  program.  This program was  established to ensure that
patients who begin treatment will have uninterrupted  access to a
full course of therapy.

o    To date,  more than 60,000  patients  have enrolled in the Access
Assurance  program.   Schering-Plough   believes  that  there  is
adequate  supply of  PEG-INTRON to meet the needs of all patients
currently on therapy.

o    Schering-Plough  believes that the Access Assurance  program will
soon  need to  transition  to a wait  list  for  newly  enrolling
patients in the U.S. Initially,  it is expected that patients put
on the wait list would be able to begin  treatment in about 10 to
12 weeks from enrolling.

o    Schering-Plough  believes  that  there is an  adequate  supply of
PEG-INTRON to meet current demand in international  markets.  The
Access  Assurance  program was  implemented for the U.S. only and
there is no similar program for other markets.

PEG-INTRON  is a  longer-action  form of INTRON(R) A  (interferon  alfa-2b,
recombinant)  Injection that uses proprietary PEG technology developed by Enzon.
Under Enzon's  licensing  agreement with  Schering-Plough,  Enzon is entitled to
royalties on worldwide sales of PEG-INTRON.  Schering-Plough  holds an exclusive
worldwide license to PEG-INTRON.

PEG-INTRON  and REBETOL  combination  therapy  received  U.S. Food and Drug
Administration  approval in August 2001 for the treatment of chronic hepatitis C
in patients with compensated liver disease who have not been previously  treated
with  interferon  alpha  and are at least 18 years of age.  The  launch  of this
combination  therapy in the U.S. was announced in October 2001. The  combination
therapy was approved for hepatitis C in the European Union in March 2001.

Except for the historical information herein, the matters discussed in this
Form 8-K include  forward-looking  statements that may involve a number of risks
and uncertainties.  Actual results may vary significantly based upon a number of
factors,  which are described in Enzon's Form 10-K,  Form 10-Qs and Form 8-Ks on
file  with  the SEC,  including  without  limitation,  risks  in  obtaining  and
maintaining regulatory approval for indications and expanded indications as well
as  manufacturing  processes,  market  acceptance of and  continuing  demand for
Enzon's products,  the effective  marketing of PEG-INTRON by Schering-Plough and
the impact of competitive products and pricing.

SIGNATURES

Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated:   January 16, 2002

ENZON, INC.
-------------------------------
(Registrant)

By: /s/ Kenneth J. Zuerblis
-------------------------------
Kenneth J. Zuerblis
Vice President,
Finance and Chief Financial Officer

2